The results obtained from mice treated with antibodies in the S100 monotherapy group showed that blocking CD8+ T cells resulted in the significant inhibition of tumor growth at late time points (Figure 6A); whereas the blockage of CD4+ T cells (Figure 6B), NK cells (Figure 6C), and macrophages (Figure 6D) produced only minimal effects, suggesting that S100 primarily exerted an anti-tumor immunity via CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.